Fingolimod

Last Updated: 09/19/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 4578 publications

Natalizumab and Tyruko (natalizumab biosimilar) for treating highly active relapsing-remitting multiple sclerosis after at least one disease-modifying therapy: a systematic review and economic model.

Natalizumab and Tyruko (natalizumab biosimilar) for treating highly active relapsing-remitting multiple sclerosis after at least one disease-modifying therapy: a systematic review and economic model.

Journal: Health technology assessment (Winchester, England)

Published: August 11, 2026

Serum Glial Fibrillary Acidic Protein Dynamics, Disease Progression, and Therapy Response in Multiple Sclerosis.

Serum Glial Fibrillary Acidic Protein Dynamics, Disease Progression, and Therapy Response in Multiple Sclerosis.

Journal: JAMA neurology

Published: August 03, 2026

Lymphatic therapies open the valve in Marfan syndrome.

Lymphatic therapies open the valve in Marfan syndrome.

Journal: The Journal of clinical investigation

Published: August 03, 2026

NPC1 deficiency engages a lysosome-genome-immune program linked to neurodegeneration and cellular aging signatures.

NPC1 deficiency engages a lysosome-genome-immune program linked to neurodegeneration and cellular aging signatures.

Journal: bioRxiv : the preprint server for biology

Published: July 29, 2026

FTY720 Increases Doxorubicin Sensitivity in Resistant Acute Myeloid Leukemia Cells.

FTY720 Increases Doxorubicin Sensitivity in Resistant Acute Myeloid Leukemia Cells.

Journal: Journal of visualized experiments : JoVE

Published: July 27, 2026

Comparative multi-analyte serum protein differences between generic and brand-name dimethyl fumarate, fingolimod, and teriflunomide in multiple sclerosis.

Comparative multi-analyte serum protein differences between generic and brand-name dimethyl fumarate, fingolimod, and teriflunomide in multiple sclerosis.

Journal: Clinical immunology (Orlando, Fla.)

Published: July 07, 2026

Impact of multiple sclerosis disease-modifying therapies on chronic lesion tissue expansion.

Impact of multiple sclerosis disease-modifying therapies on chronic lesion tissue expansion.

Journal: Multiple sclerosis (Houndmills, Basingstoke, England)

Published: July 01, 2026

Fungal Infections Associated with Sphingosine 1-Phosphate Receptor Modulators: Immunological Mechanisms, Clinical Patterns, and Management Considerations.

Fungal Infections Associated with Sphingosine 1-Phosphate Receptor Modulators: Immunological Mechanisms, Clinical Patterns, and Management Considerations.

Journal: Microorganisms

Published: July 01, 2026

Brain-Derived Proteins Induce Autoimmune Responses via MBP-IgG Immune Complexes and Participate in Pulmonary Edema Following Traumatic Brain Injury.

Brain-Derived Proteins Induce Autoimmune Responses via MBP-IgG Immune Complexes and Participate in Pulmonary Edema Following Traumatic Brain Injury.

Journal: Journal of neurotrauma

Published: June 16, 2026

Virus-specific CD8 T cells rapidly populate and persist in skull bone marrow after brain infection.

Virus-specific CD8 T cells rapidly populate and persist in skull bone marrow after brain infection.

Journal: Research square

Published: June 12, 2026

Virus-specific CD8 T cells rapidly populate and persist in skull bone marrow after brain infection.

Virus-specific CD8 T cells rapidly populate and persist in skull bone marrow after brain infection.

Journal: Research square

Published: June 12, 2026

Response to "Nanoformulated fingolimod for spinal cord injury: promising anti‑neuroinflammatory effects but unsubstantiated bioavailability claims".

Response to "Nanoformulated fingolimod for spinal cord injury: promising anti‑neuroinflammatory effects but unsubstantiated bioavailability claims".

Journal: Spinal cord

Published: June 10, 2026

Showing 1-12 of 4,578

Last Updated: 09/19/2026